Twice‐Weekly Micafungin as Antifungal Prophylaxis in Children Undergoing Hematopoietic Stem Cell Transplantation
Pediatric Transplantation · 2026-03 · 30 (3)
DOI: 10.1111/petr.70296 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Transplantation, online erschienen am 12.03.2026. Verfasst von Syaza Ab Rahman und 3 weiteren Autor:innen. Beteiligte Einrichtung: Bone Marrow Transplantation Unit, Department of Pediatrics, Universiti Malaya Medical Centre, Kuala Lumpur, Federal Territory of Kuala Lumpur, Malays…. Hauptthemen laut MEDLINE: Micafungin, Antifungal Agents, Hematopoietic Stem Cell Transplantation, Invasive Fungal Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Children undergoing hematopoietic stem cell transplantation are at increased risk of developing invasive fungal infection. Micafungin is an echinocandin with broad‐spectrum antifungal properties. Recent trials have reported on the efficacy of intermittent daily dosing of micafungin for fungal prophylaxis in pediatric patients undergoing transplantation, with success rates of 76%–99%, success defined as absence of proven, probable, or possible invasive fungal infection. We implemented a twice‐weekly micafungin regimen as antifungal prophylaxis in our unit. Patients and Methods One hundred consecutive transplants performed between May 2018 and February 2024 were analyzed. Micafungin prophylaxis was dosed at 3–5 mg/kg daily given twice weekly from Day 0 till stable neutrophil engraftment, after which oral fluconazole was prescribed till Day +100. Fungal infection status was evaluated by radiological procedures and cultures from blood or sterile body sites as clinically indicated. The primary endpoint of the study was the evaluation of efficacy; secondary endpoints were safety and tolerability.
Results
Ninety three patients who underwent 95 transplants fulfilled the inclusion criteria. Underlying diagnoses were: leukemia (47), inborn errors of immunity (11), other malignancies (11), hemoglobinopathy (8), and others (16). There were no proven or probable fungal infections. Seventeen patients (18%) required change from prophylaxis to empirical antifungal treatment for persistent fever ( n = 5) and possible fungal infections, mainly oesophagitis ( n = 8). All patients who failed micafungin prophylaxis received allogeneic transplants, and HLA‐haploidentical was the majority (14/17). None of the patients had to discontinue micafungin due to safety or tolerability concerns.
Conclusions
Twice‐weekly IV micafungin is a safe and effective option as antifungal prophylaxis for children undergoing HSCT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Bone Marrow Transplantation Unit, Department of Pediatrics, Universiti Malaya Medical Centre, Kuala Lumpur, Federal Territory of Kuala Lumpur, Malaysia.
- Department of Pediatrics, Hospital Sultan Ismail, Johor Bahru, Johor, Malaysia.
ORCID-Profile: Syaza Ab Rahman, Xin Yee Chiew, Vida Jawin, Hany Ariffin
Zitieren
APA
Ab Rahman, S., Chiew, X. Y., Jawin, V., & Ariffin, H. (2026). Twice‐Weekly Micafungin as Antifungal Prophylaxis in Children Undergoing Hematopoietic Stem Cell Transplantation. Pediatric Transplantation, 30(3). https://doi.org/10.1111/petr.70296
Vancouver
Ab Rahman S, Chiew XY, Jawin V, Ariffin H. Twice‐Weekly Micafungin as Antifungal Prophylaxis in Children Undergoing Hematopoietic Stem Cell Transplantation. Pediatric Transplantation. 2026;30(3). doi:10.1111/petr.70296
BibTeX
@article{AbRahman2026,
author = {Ab Rahman, Syaza and Chiew, Xin Yee and Jawin, Vida and Ariffin, Hany},
title = {Twice‐Weekly Micafungin as Antifungal Prophylaxis in Children Undergoing Hematopoietic Stem Cell Transplantation},
journal = {Pediatric Transplantation},
year = {2026},
volume = {30},
number = {3},
doi = {10.1111/petr.70296}
}
EUVIMED